Sugi Predict

Sugi Predict / Compounds / SCHEMBL8134274

SCHEMBL8134274

SCHEMBL8134274

CC(C)C[C@H](NC(=O)Cc1ccc(C(=O)O)c(O)c1)c1ccccc1N1CCCCC1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCC8 Q09428 3/20 0.79
▸ CYP3A4 P08684 4/20 0.77
▸ SLC22A1 O15245 1/20 0.77
▸ ABCC3 O15438 1/20 0.77
▸ ABCC4 O15439 1/20 0.77
▸ NR1I2 O75469 1/20 0.77
▸ ABCB11 O95342 1/20 0.77
▸ LMNA P02545 1/20 0.77
▸ ADORA3 P0DMS8 1/20 0.77
▸ HTR2A P28223 1/20 0.77
▸ MAPK1 P28482 1/20 0.77
▸ ADRA1A P35348 1/20 0.77
▸ PTGS2 P35354 1/20 0.77
▸ PDE4D Q08499 1/20 0.77
▸ NR1I3 Q14994 1/20 0.77
▸ ABCC2 Q92887 1/20 0.77
▸ NR1H4 Q96RI1 1/20 0.77
▸ KCNQ2 O43526 8/20 0.41
▸ GAA P10253 4/20 0.41
▸ GFER P55789 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4096071 1.00 ABCC8 (0.79) ABCC8CYP3A4SLC22A1ABCC3ABCC4
SCHEMBL7888681 0.90 ABCC8 (0.66) ABCC8CYP3A4SLC22A1ABCC3ABCC4
Repaglinide SCHEMBL29373506 0.87 ABCC8 (1.00) ABCC8CYP3A4SLC22A1ABCC3ABCC4
Repaglinide SCHEMBL1536902 0.87 ABCC8 (1.00) ABCC8CYP3A4SLC22A1ABCC3ABCC4
Repaglinide SCHEMBL16137 0.87 ABCC8 (1.00) ABCC8CYP3A4SLC22A1ABCC3ABCC4
Repaglinide SCHEMBL8141950 0.87 ABCC8 (1.00) ABCC8CYP3A4SLC22A1ABCC3ABCC4
Repaglinide SCHEMBL163867 0.87 ABCC8 (1.00) ABCC8CYP3A4SLC22A1ABCC3ABCC4
Repaglinide SCHEMBL29598841 0.87 ABCC8 (1.00) ABCC8CYP3A4SLC22A1ABCC3ABCC4
Repaglinide SCHEMBL29392295 0.87 ABCC8 (1.00) ABCC8CYP3A4SLC22A1ABCC3ABCC4
Repaglinide SCHEMBL6240755 0.87 ABCC8 (0.98) ABCC8CYP3A4SLC22A1ABCC3ABCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209587-A1 REPAGLINIDE FORMULATIONS DR. REDDY'S LABORATORIES LIMITED (IN) 2009-08-20 — — US disclosed
US-20090209587-A1 REPAGLINIDE FORMULATIONS DR. REDDY'S LABORATORIES LIMITED (IN) 2009-08-20 — — US disclosed
WO-2008099286-A2 IMPROVED PROCESS FOR PREPARING ETHYL (S)-2-ETHOXY-4-[N-[1-(2- PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYL METHYL]BENZOATE AND USE THEREOF FOR THE PREPARATION OF REPAGLINIDE ACTAVIS GROUP PTC EHF (US) 2008-08-21 — — WO disclosed
WO-2008028914-A1 COMBINATION TREATMENT FOR DIABETES MELLITUS NYCOMED GMBH (DE) 2008-03-13 — — WO disclosed
US-6143769-A ENANTIOMORPH KARL THOMAE GMBH (DE) 2000-11-07 — — US disclosed
US-5312924-A Compounds for lowering blood sugar and effecting metabolism DR. KARL THOMAE GMBH (DE) 1994-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209587-A1 REPAGLINIDE FORMULATIONS GCG, GCGR, GLP1R ABCC8 1443/4885CYP3A4 185/4885SLC22A1 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.